Search
Columbus, OH Paid Clinical Trials
A listing of 1259 clinical trials in Columbus, OH actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
865 - 876 of 1259
There are currently 1259 clinical trials in Columbus, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Nationwide Children's Hospital, Ohio State University Comprehensive Cancer Center, Ohio State University and The Ohio State University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
Recruiting
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery.
All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their ba... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Ohio State University Medical Center, Columbus, Ohio
Conditions: Atrial Fibrillation, Stroke, Bleeding
Prospective Case Collection Study for New Mammography Technologies
Recruiting
To evaluate the safety and efficacy of the proposed investigational device and assess its clinical utility in breast cancer screening and diagnosis to support continuing technology development of the investigational technology.
Gender:
FEMALE
Ages:
Between 35 years and 100 years
Trial Updated:
02/05/2025
Locations: Solis Mammography Columbus, Columbus, Ohio
Conditions: Mammography
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
Recruiting
This phase II trial studies how well a biologically optimized infusion schedule of gemcitabine and nab-paclitaxel works in treating patients with pancreatic cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Altering the timing of the nab-paclitaxel infusion may... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
MyAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
Recruiting
Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages II-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
02/05/2025
Locations: Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: COPD
Feasibility and Reliability of the Melbourne Assessment-2 (MA-2) for Telehealth
Recruiting
The goals of this study:
1. Determine if a play based test of arm and hand movements is valid and reliable when conducted through telehealth for children with hemiplegic cerebral palsy.
2. Measure differences in parent, provider and child engagement when an assessment is conducted in-person compared to via telehealth.
3. Rate caregivers' overall impressions of procedures when an assessment is conducted in-person compared to telehealth.
Participants will attend two visits, one in person and one... Read More
Gender:
ALL
Ages:
Between 2 years and 10 years
Trial Updated:
02/04/2025
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Cerebral Palsy, Hemiplegic Cerebral Palsy
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
Recruiting
This is a phase 3, open label, single arm study of padeliporfin in the treatment of Upper Tract Urothelial Carcinoma (UTUC). The ENLIGHTED study will recruit patients with low-grade non-invasive upper tract urothelial carcinoma in either the kidney or the ureter. Patients will be treated with padeliporfin VTP in two phases: an Induction Treatment Phase and a Maintenance Treatment Phase and will be followed up for up to an additional 48 months in the long term (non intervention) follow up phase w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: The Ohio State University (OSU), Columbus, Ohio
Conditions: Transitional Cell Cancer of Renal Pelvis and Ureter
Retrospective Acute Care Appendectomy Study
Recruiting
The purpose of this retrospective study is to compare perioperative data for subjects who have undergone an emergent or urgent robotic-assisted or laparoscopic appendectomy for acute appendicitis.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
02/04/2025
Locations: The Ohio State University, Columbus, Ohio
Conditions: Acute Appendicitis
Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis
Recruiting
This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: OhioHealth, Columbus, Ohio
Conditions: Myelofibrosis
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Ohio State University Brain and Spine Hospital, Columbus, Ohio
Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation
Occupational Therapy and Registered Dietitian Services to Reduce Fall Risk Among Home Delivered Meal Clients
Recruiting
The purpose of this study is to determine which of the following four service models is most effective for reducing fall risk among home-delivered meal clients: (1) meals alone, (2) meals + registered dietitian services, (3) meals + occupational therapy services, (4) meals + registered dietitian + occupational therapy services.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
02/02/2025
Locations: LifeCare Alliance, Columbus, Ohio
Conditions: Diet, Food and Nutrition, Accidental Falls, Cardiovascular Diseases, Diabetes, Debility, Frailty, Functional Disability
Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
Recruiting
The purpose of this Phase 3 study is to determine whether iptacopan (LNP023) is efficacious and safe for the treatment of aHUS in adult patients who are treatment naive to complement inhibitor therapy.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/31/2025
Locations: Comprehensive Transplant Ctr at OSU, Columbus, Ohio
Conditions: Atypical Hemolytic Uremic Syndrome
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Recruiting
This phase II trial tests how well zanubrutinib and lisocabtagene maraleucel (liso-cel) work together in treating patients with Richter's syndrome. Richter's syndrome occurs when chronic lymphocytic leukemia and/or small lymphocytic leukemia transforms into an aggressive lymphoma, which is a cancer of the lymph nodes. Zanubrutinib is a class of medication called a kinase inhibitor. These drugs work by preventing the action of abnormal proteins that tell cancer cells to multiply, which helps stop... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Transformed
865 - 876 of 1259